Tivozanib Confirmed Superior to Sorafenib For Treatment of Refractory Metastatic RCC
May 29th 2020"We believe the TIVO-3 data demonstrate a favorable risk/benefit profile for tivozanib in the growing population of patients who have relapsed or become refractory to multiple lines of therapy, including checkpoint inhibitors."
Read More
Co-Inhibition of TIGIT and PD-L1 Generates Promising Efficacy in NSCLC
May 29th 2020Frontline treatment with the TIGIT inhibitor tiragolumab plus atezolizumab demonstrated greater efficacy versus single-agent checkpoint inhibitor therapy in locally advanced or metastatic non–small cell lung cancer, according to results of the phase 2 CITYSCAPE trial reported at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
Read More
Encouraging Preliminary Findings Demonstrated for Belantamab Mafodotin Combo in R/R Multiple Myeloma
May 29th 2020“Preliminary data for the 18 patients who have received belantamab mafodotin 2.5 mg/kg single dosing with bortezomib/dexamethasone suggests that this combination has an acceptable safety profile with no new safety signals identified. Clinical response looks promising."
Read More
Improved Responses Achieved for R/R Multiple Myeloma With Selinexor Combo
May 29th 2020Selinexor in combination with bortezomib and dexamethasone resulted in improvements in responses and outcomes compared with bortezomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma, according to findings from the phase 3 BOSTON trial from the 2020 ASCO Virtual Scientific Program.
Read More
PFS Data Show Carfilzomib Triplet Remains Inferior to VRd in Newly Diagnosed Myeloma
May 29th 2020Given the higher efficacy of carfilzomib seen in recent phase 2 trials, investigators sought to determine if carfilzomib could replace bortezomib in the current standard of care triplet induction regimen in standard and intermediate risk NDMM, but the study failed.
Read More
Overall Survival Not Increased With Locoregional Therapy in Advanced Breast Cancer
May 28th 2020"Based on the results of our study, women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumor with the expectation of a survival benefit."
Read More
Adjuvant Osimertinib Leads to Significant Boost in DFS in Early-Stage EGFR+ NSCLC
May 28th 2020"Adjuvant osimertinib is the first targeted agent in a global randomized trial to show a statistically significant and clinically meaningful improvement in disease-free survival in patients with stage IB/II/IIIA EGFR mutation–positive non–small cell lung cancer."
Read More
Pembrolizumab Extends PFS in Newly Diagnosed MSI-H/dMMR mCRC
May 28th 2020"Pembrolizumab works in non-randomized studies in this group of patients with advanced disease. This randomized study demonstrates a huge benefit in the first-line [setting] with pembrolizumab and should be the new standard of care."
Read More
Promising Efficacy and Safety With Seleno-L-Methionine Plus Axitinib in ccRCC
May 16th 2020Yousef Zakharia, MD, discussed recent phase I data from a study of seleno-L-methionine in combination with axitinib as treatment of patients with previously treated or relapsed clear cell renal cell carcinoma. Zakharia recently presented these data as part of the American Urological Association Virtual Experience platform for the 2020 AUA Annual Meeting.
Watch
UGN-102 May Serve as Surgical Alternative for Low-Grade NMIBC With Intermediate Risk
May 15th 2020"These interim data demonstrate that primary chemoablation of low-grade intermediate-risk non–muscle invasive bladder cancer using UGN-102 results in a significant treatment response and encouraging durability."
Read More
Clinical Activity With Pembrolizumab/Enzalutamide Emboldens Further Study in mCRPC
May 15th 2020Positive safety and efficacy outcomes were witnessed in the KEYNOTE-365 study , supporting further assessment of the combination of pembrolizumab and enzalutamide in a larger population of patients with metastatic castration resistance prostate cancer.
Read More
Neoadjuvant Apalutamide Leads to Reduced Tumor Volume in High-Risk Prostate Cancer
May 15th 2020"Historically, neoadjuvant hormone therapy has been shown to improve pathologic outcomes. Therefore, neoadjuvant androgen deprivation therapy may allow a nerve-sparing surgical approach to increase post-surgical quality-of-life outcomes without compromising oncologic outcomes.”
Read More
Two Analyses Describe Patient Preferences for Maintenance Therapy in Ovarian Cancer
April 25th 2020In an interview with Targeted Oncology, Charlotte Sun, DrPH, MPH, discussed the findings from 2 abstracts from the 2020 SGO Annual Meeting on patient preferences for maintenance therapy in ovarian cancer and how these findings can be applied to practice in the community oncology setting.
Read More
Dostarlimab on the Road to Progress in dMMR Endometrial Cancer
April 24th 2020“There are limited treatment options for women with advanced or recurrent endometrial cancer, and prognosis of these patients is poor. The results observed in the GARNET trial indicate the potential of dostarlimab to offer a new treatment option for women with this challenging disease.”
Read More
Olaparib Matches Chemotherapy Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer
April 17th 2020Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival over chemotherapy.
Read More
Veliparib Spotlighted for Antitumor Efficacy in Ovarian Cancer
April 15th 2020In the phase III VELIA trial, the addition of veliparib to frontline induction chemotherapy expanded the number of complete responses and CA-125 responses in patients with high-grade serous ovarian cancer compared with chemotherapy alone, according to results from an exploratory analysis.
Read More